GlassScriptPhysician profile
Laura L May
NPI 1851055776
$7,390.28
in general payments reported to CMS, 2019-2025
40 companies · $2,681 in 2025
The $2,681 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $229 · 2022: $1,002 · 2023: $640 · 2024: $2,838 · 2025: $2,681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,941 · Travel and Lodging: $1,138 · Education: $80.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,941.35 |
| Travel and Lodging | $1,138.28 |
| Education | $80.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,173.39 | 2022-2024 | Minimed 780g |
| Novo Nordisk INC | $1,011.51 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $790.49 | 2022-2025 | Tepezza, Evenity, Repatha |
| Corcept Therapeutics | $425.59 | 2021-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $329.52 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Lilly USA, LLC | $305.37 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Ascendis Pharma Endocrinology INC | $247.33 | 2023-2025 | Yorvipath |
| Antares Pharma, INC. | $218.84 | 2022-2025 | Xyosted |
| Recordati_rare_diseases_inc. | $182.77 | 2023-2025 | Isturisa, Signifor Lar |
| Mannkind Corporation | $166.42 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $152.96 | 2022-2024 | |
| Dexcom, INC. | $143.70 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.51 | 2023-2025 | Jardiance |
| Edwards Lifesciences Corporation | $128.75 | 2021 | |
| Cequr Corporation | $110.35 | 2022-2025 | Cequr Simplicity |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $107.16 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $95.19 | 2023-2025 | Unithroid |
| Horizon Therapeutics Plc | $71.34 | 2023 | Tepezza |
| Abbvie INC. | $70.27 | 2025 | |
| Insulet Corporation | $65.58 | 2024-2025 | Omnipod |
| Madrigal Pharmaceuticals | $38.48 | 2025 | Rezdiffra |
| Amphastar Pharmaceuticals, INC. | $37.63 | 2025 | |
| Beta Bionics, INC. | $35.13 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Nevro Corp. | $34.83 | 2022 | |
| Tolmar, INC. | $33.63 | 2024 | |
| Ibsa Pharma INC. | $29.20 | 2022-2025 | Licart, Flector, Tirosint |
| Rgh Enterprises LLC | $29.00 | 2025 | |
| Tandem Diabetes Care, INC. | $24.52 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astellas Pharma US INC | $20.33 | 2023 | Veozah |
| Sanofi-Aventis U.S. LLC | $20.27 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $19.64 | 2024 | Crysvita |
| Averitas Pharma INC. | $17.74 | 2023 | Qutenza |
| Evoke Pharma, INC. | $16.75 | 2025 | |
| Verity Pharmaceuticals INC. | $16.37 | 2024 | Tlando |
| Esperion Therapeutics, INC. | $15.00 | 2024 | Nexletol |
| Pfizer INC. | $14.58 | 2024 | |
| Chiesi USA, INC. | $14.23 | 2024 | Mycapssa |
| Novartis Pharmaceuticals Corporation | $13.25 | 2023 | |
| Grt US Holding, INC. | $13.00 | 2022 | |
| Amryt Pharma Holdings LTD | $11.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.